Transparency Market Research (TMR) has published a new
report on the pseudomonas
aeruginosa infection treatment market for the forecast period of 2019–2027. According to the report, the global pseudomonas aeruginosa
infection treatment market was valued at ~US$
1 Bn in 2018, and is projected to expand at a CAGR of ~6% from 2019 to
2027.
Request Brochure –
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=17156
Pseudomonas
Aeruginosa Infection Treatment Market: Overview
·
The
global pseudomonas aeruginosa infection treatment market is anticipated to be
driven by rapidly growing antibacterial resistance, increase in incidences of
nosocomial infections associated with P. aeruginosa, need for new
broad-spectrum agents, and rich product pipeline of pseudomonas aeruginosa
infection treatments.
·
Europe
captured a major share of the global pseudomonas aeruginosa infection treatment
market in 2018, due
to the presence of a large population with this type of infection, increase in
incidences of various types of hospital-acquired infections caused by P.
aeruginosa, and rapid adoption of technologically-advanced products.
·
The
pseudomonas aeruginosa infection treatment market in Asia Pacific is expected
to expand at a high CAGR of ~7% from 2019 to 2027 due
to rise in awareness, adoption of expansion strategies, and robust pipeline of
new therapeutics in clinical trials.
Request COVID Analysis on Pseudomonas Aeruginosa Infection Treatment Market
–
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=17156
Increase
in Incidences of Nosocomial Infections Associated with P. Aeruginosa to Propel
Market
·
Rise
in the prevalence of nosocomial infections associated with P. aeruginosa, such
as pneumonia, urinary tract infection, cystic fibrosis, blood stream infection,
and others, are likely to augment the global pseudomonas aeruginosa infection
treatment market during the forecast period.
·
Increase
in incidences of bacterial infections i.e., pseudomonas aeruginosa infections,
in intensive care with no effective treatment is projected to drive the demand
for newer pseudomonas aeruginosa infection treatment drugs.
·
According
to Centers for Disease Control and Prevention (CDC) estimates, around 51,000
healthcare-associated P. aeruginosa infections occur in the U.S. each year.
More than 6,000 (13%) of these are multidrug-resistant, with roughly 400 deaths
per year attributed to these infections.
Cephalosporin Drug Class to be
Prominent
·
In
terms of drug class, the global pseudomonas aeruginosa infection treatment
market has been classified into aminoglycoside, cephalosporin, carbapenem,
monobactam, and others
·
The
cephalosporin segment dominated the global pseudomonas aeruginosa infection
treatment market in 2018. The
segment is anticipated to lose some market share during the forecast period.
Major pharmaceutical companies are focusing on developing new class of
cephalosporin for the treatment of various P. aeruginosa infections. This is
expected to fuel the growth of the cephalosporin segment.
·
Moreover,
new cephalosporin (fifth-generation) was developed for the treatment of gram
negative bacteria such as P. aeruginosa, methicillin-resistant staphylococcus
aureus, and others. The launch of new cephalosporin class of drugs is likely to
boost the growth of the segment.
Request Customization on Pseudomonas Aeruginosa Infection Treatment Market
Report –
https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=17156
Combination
Therapy to be Most Attractive
·
In
terms of medication type, the global pseudomonas aeruginosa infection treatment
market has been classified into monotherapy and combination therapy.
·
The
combination therapy segment dominated the global pseudomonas aeruginosa
infection treatment market in 2018. Increase in
drug resistance in monotherapy has resulted in a rise in the demand for
combination therapy for the treatment of P. aeruginosa infection. Combination
therapy helps increase compliance, synergy, and efficacy, and reduce side
effects and cost. These factors are projected to boost the growth of the
combination therapy segment.
·
Additionally,
the growth of combination therapy for treatment of pseudomonas aeruginosa
infection is attributed to the rapid onset of action, high bioavailability
rate, cost saving, and high efficiency.
Intravenous is Most Preferred Route
of Administration
·
In
terms of route of administration, the global pseudomonas aeruginosa infection
treatment market has been classified into nasal, oral, and intravenous
·
The
intravenous segment dominated the global pseudomonas aeruginosa infection
treatment market in 2018. Most of the
drugs available for intravenous route, high accuracy in dosing, and rapid onset
of action compared to other routes are anticipated to propel the intravenous
segment.
·
Most
physicians prefer the intravenous route for the administration of drugs,
because the entire administered dose reaches the systemic circulation
immediately, resulting in the rapid onset of action against bacteria.
Buy Pseudomonas Aeruginosa
Infection Treatment Market Report –
https://www.transparencymarketresearch.com/checkout.php?rep_id=17156<ype=S
Hospital
Pharmacies Gaining Prominence
·
Based
on distribution channel, the global pseudomonas aeruginosa infection treatment
market has been segmented into hospital pharmacies, retail pharmacies, and
online pharmacies.
·
The
hospital pharmacies segment dominated the global pseudomonas aeruginosa
infection treatment market in 2018. This is due to an increase in the number of
multi-specialty hospitals in developing countries.
·
Additionally,
well-developed infrastructure and increase in the adoption of new products by
hospital pharmacies are likely to propel the segment during the forecast
period.
Europe a Prominent Market, While
Asia Pacific to Offer High Incremental Opportunity
·
In
terms of region, the global pseudomonas aeruginosa infection treatment market
has been segmented into North America, Europe, Latin America, Asia Pacific, and
the Middle East & Africa. Europe is anticipated to account for a leading
share of the global pseudomonas aeruginosa infection treatment market during
the forecast period, owing to an increase in the number of patients suffering
from pseudomonas aeruginosa infection. For instance, an estimated 22,000 to
33,000 people are suffering from pseudomonas aeruginosa infection in Germany.
·
Moreover,
the presence of major players and the early adoption of new products boost the
growth of the pseudomonas aeruginosa infection treatment market in Europe.
·
The
pseudomonas aeruginosa infection treatment market in Asia Pacific is projected
to grow at a rapid pace in the next few years. India, China, and South Korea
are expected to be lucrative markets for pseudomonas aeruginosa infection
treatment in the near future, owing to the rise in the prevalence of
healthcare-associated pseudomonas aeruginosa infection, rapidly developing
healthcare infrastructure, and increase in awareness and demand for advanced
therapeutics.
·
According
to a recent study, 165,000 to 180,000 people in Australia suffer from
hospital-acquired infections; of these, around 9,000 have pseudomonas
aeruginosa infection.
Growth Strategies of Key Players in
the Global Pseudomonas Aeruginosa Infection Treatment Market
·
Major
players operating in the global pseudomonas aeruginosa infection treatment
market are Allergan plc, Teva Pharmaceutical Industries Ltd.,
Pfizer, Inc., Lupin Pharmaceuticals, Inc., AstraZeneca, Merck & Co., Inc.,
Bristol-Myers Squibb Co., and Janssen Pharmaceuticals, Inc., among others.
·
Companies
operating in the global pseudomonas aeruginosa infection treatment market
engage in research and development as well as strategic collaborations and
partnerships for new product launches and to expand their product offerings and
customer base. For instance, in June 2018, Lupin
Limited launched generic Tobramycin Inhalation Solution USP in the U.S. for the
treatment of cystic fibrosis patients with P. aeruginosa.
·
In March 2019, Allergan received U.S. FDA
approval for the AVYCAZ treatment of complicated intra-abdominal infections
(cIAI) and urinary tract infections (cUTI) in pediatric patients.
About Us
Transparency
Market Research is a global market intelligence company, providing global
business information reports and services. Our exclusive blend of quantitative
forecasting and trends analysis provides forward-looking insight for thousands
of decision makers. Our experienced team of Analysts, Researchers, and
Consultants, use proprietary data sources and various tools and techniques to
gather, and analyze information.
Our data
repository is continuously updated and revised by a team of research experts,
so that it always reflects the latest trends and information. With a broad research
and analysis capability, Transparency Market Research employs rigorous primary
and secondary research techniques in developing distinctive data sets and
research material for business reports.
Contact
Transparency
Market Research,
90 Sate Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com
